Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.

ABSTRACT:

Importance

Trastuzumab deruxtecan (T-DXd) has shown efficacy in patients with breast cancer with ERBB2 immunohistochemistry (IHC) scores of 1+ or 2+ but not 0 as read in central pathology laboratories. The drug is currently being tested in large randomized clinical trials with registration intent for this patient population.

Objective

To determine the suitability of the current standard ERBB2 IHC assays to select patients with low ERBB2 positivity for treatment with T-DXd.

Design and setting

Assessment of data from College of American Pathologists surveys and assessment of analytic data from a Yale University-based study of concordance of 18 pathologists reading 170 breast cancer biopsies.

Results

The total survey data set included scores over 2 years from 1391

SUBMITTER: Fernandez AI 

PROVIDER: S-EPMC8814969 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature